WallStSmart

Burning Rock Biotech Ltd (BNR)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Natera Inc generates 426% more annual revenue ($2.71B vs $514.43M). NTRA leads profitability with a -7.1% profit margin vs -11.5%. NTRA earns a higher WallStSmart Score of 31/100 (F).

BNR

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -4.98

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 0.82

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNR2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
37.7%10/10

Revenue surging 37.7% year-over-year

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

BNR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$129.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-10.7%2/10

ROE of -10.7% — below average capital efficiency

Revenue GrowthGrowth
-18.9%2/10

Revenue declined 18.9%

NTRA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
25.9x2/10

Trading at 25.9x book value

Return on EquityProfitability
-10.6%2/10

ROE of -10.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BNR

The strongest argument for BNR centers on Debt/Equity, Price/Book.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.

Bear Case : BNR

The primary concerns for BNR are EPS Growth, Market Cap, Return on Equity.

Bear Case : NTRA

The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

BNR profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.53 — expect wider price swings.

NTRA is growing revenue faster at 37.7% — sustainability is the question.

NTRA generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

BNR scores higher overall (31/100 vs 31/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Burning Rock Biotech Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · China

Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?